<DOC>
	<DOCNO>NCT02274233</DOCNO>
	<brief_summary>The purpose study assess safety amount study drug blood increase dos SP-420 . The study conduct patient β-thalassemia .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study Escalating Doses SP-420 , Iron Chelator , Patients With β-Thalassemia</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Subject ironoverload secondary βthalassemia require chronic red blood cell transfusion iron chelation therapy Subject weigh ≥35 kg Subject willing discontinue current iron chelation therapy least 7 day prior first dose SP420 duration study Serum ferritin ≥700 ng/mL iron saturation ≥70 % within 3 week Baseline ( Day 1 ) Cardiac T2* score &gt; 20 msec within 6 month Baseline ( Day 1 ) Willing use contraception study Pregnant breastfeeding Serum creatinine great upper limit normal Platelet count &lt; 100 × 10^9/L Use another investigational drug within last 30 day Significant cardiac , renal , hepatic dysfunction clinically significant condition , opinion Investigator , would exclude subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Chelation</keyword>
	<keyword>Iron Overload</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Transfusion</keyword>
	<keyword>Iron Chelation</keyword>
</DOC>